Background Patients with critical limb ischaemia have a high rate of amputation and mortality. We tested the hypothesis that non-viral 1 fi broblast growth factor (NV1FGF) would improve amputation-free survival.
Introduction
Peripheral artery disease 1, 2 aff ects up to 20 million individuals in North America and Europe, with 2-5% developing the most severe form of the disease, critical limb ischaemia. This disorder is most often caused by atherosclerosis, but has a worse natural history than that of patients presenting with stable coronary or cerebrovascular disease. Although outcome is poorly documented, studies have supported the contention that prognosis is poor. [3] [4] [5] [6] For example, 46% of patients unsuitable for revascularisation will have major amputation within 12 months, 3 with the substantial morbidity that this procedure entails. 2 years after a belowknee amputation, no more than 40% of the amputees will have reached full mobility, 15% will have had contralateral amputation and 15% an above-knee amputation, and 30% will have died. 4 Results from studies 5, 6 have shown that the quality of life of a patient with critical limb disease equates to cancer patients with terminal disease.
In 1991, the European Working Group on Critical Limb Ischaemia concluded that no medical treatment had been shown to alter this natural history, 7 and little progress has been reported since then. Despite the success of limb salvage with leg bypass, this procedure remains associated with a substantial morbidity and mortality, 8 with the need for subsequent surgery and hospitalisation for wound complications as high as 50%. Furthermore, in a substantial proportion of patients, poor general health, or lack of a suitable vein for revascularisation precludes open surgery, and the multifocal distribution and extent of the arterial occlusive disease might also make both open surgical or endovascular revascularisation impossible. At present, no eff ective alternatives to either percutaneous or surgical revascularisation in patients with critical limb ischaemia exist. 9, 10 Techniques to improve the perfusion of the ischaemic leg by less invasive means are needed. Substantial research has focused on development of therapeutic angiogenesis. In a meta-analysis 11 of trials that included gene and cell-based therapies in peripheral artery disease, the investigators concluded that these therapies had the potential for clinical benefi t.
Fibroblast growth factor type 1 (FGF1) modulates and enhances new blood-vessel formation 12 and activates migration, proliferation, and diff erentiation of endothelial cells, which result in sprouting of capillaries from pre-existing vessels. Non-viral 1 (NV1) FGF (riferminogene pecaplasmid), a naked DNA plasmid that includes the gene encoding for human FGF1, given intramuscularly into the calf and thigh leads to expression of human FGF1 protein.
Results from studies in human beings of intramuscular administrations of NV1FGF showed expression of FGF1, and those from studies in animals [12] [13] [14] showed restoration of a functional vascular network near the site of administration.
In an open label phase 1 trial of 51 patients, 15 one intramuscular administration of NV1FGF in patients with critical limb ischaemia signifi cantly improved symptoms (pain, ulcer size) and haemodynamic variables in the treated limb. 15 In the phase 2 TALISMAN trial, 16 administration of NV1FGF (4 mg every 2 weeks) showed a similar improvement in ulcer healing (the primary endpoint) to that of placebo, but a 62·9% reduction of the risk of major amputation (p=0·015) and a 56% reduction of the risk of major amputation or death (p=0·009) at 12 months as compared with placebo.
The main objective of this study was to show the clinical benefi t of NV1FGF in delay of the time to major amputation or death in patients with clinical limb ischaemia with non-healing ischaemic skin lesions, in whom revascularisation was not possible.
Methods

Patients
This TAMARIS study is a multinational, double-blind, placebo-controlled phase 3 randomised gene therapy trial (EFC6145), in critical limb ischaemia. Trial recruitment was from Dec 1, 2007 <30 mm Hg) and by one imaging technique (angiography or doppler examination). Vascular surgeons had to confi rm that patients were unsuitable for revascularisation and to justify this decision to the independent adjudication panel (event adjudication committee). Panel 1 shows the major inclusion and exclusion criteria. The research protocol was approved by the relevant institutional review boards or ethics committees and all patients gave written informed consent.
Randomisation and masking
Eligible patients were randomly assigned to receive either NV1FGF or placebo (ratio 1:1). Randomisation was stratifi ed by diabetes status and by country and managed centrally by a central interactive voice response system (IVRS). The randomisation code list, with a block size of four, was generated by the sponsor with an electronic technique. The investigator, patient, and sponsor study teams were masked to treatment. Both the active compound (NV1FGF) and the placebo (saline solution) were similar in their appearance (transparent solution) and could not be distinguished from one another.
Procedures
If the disease aff ected both legs and both were unsuitable for revascularisation, the leg with the lowest pressure index (ankle brachial index or toe brachial index) was identifi ed as the leg to be treated (index leg). The data for the other leg were recorded in the case-report form but not analysed for effi cacy. To aid standardisation, the methods used to assess skin lesions were clearly defi ned in the case-record form, which contained observer descriptions of ulcer sites, sizes, depths, texture (dry, moist, or gangrenous), and description of lesion management. Four treatment sessions were done 2 weeks apart. At every session, eight intramuscular injections of 0·5 mg NV1FGF each were given in the leg to be treated: four into the calf muscle covering the anterior and posterior region and four into the thigh muscle of the ischaemic leg. The injection sites were selected according to an accessible good striated muscle mass and as close as possible to areas of known collateral blood fl ow development. In patients with poor muscle mass, the investigator was allowed to identify the injection sites using B-mode ultrasound.
Investigators were advised to use present guidelines for optimum medical management of patients. Figure 1 shows the study design. All patients were reviewed at 2, 4, and 6 weeks during the treatment phase, and then at 3, 6, 9, and 12 months in the observation phase for assessment of both effi cacy and safety. An exploratory extended observation phase to assess long-term safety is in progress, in which the patients will be reviewed at 18, 24, 30, and 36 months.
Endpoints
The primary combined endpoint of the trial was time to major amputation (above the ankle) of the treated leg or death from any cause in the study period of 12 months. All amputations were documented by anatomical level and indication (continuing ischaemia detrimental to the patient's health; presence of a lesion considered unlikely to heal; substantial infection, gangrene, or osteomyelitis such that the patient's life was endangered; and intolerable pain).
The main secondary endpoints were major amputation and death from any cause in the study period of 12 months analysed separately. Other secondary endpoints were: (1) all amputations, including all minor and major amputations on the treated leg; (2) skin lesion status (worsened, unchanged, improved, fully healed lesion); (3) pain intensity as assessed at rest (VAS Scale); 17 (4) functionality and general health assessmentambulatory function and residential status for patients according to the Deneuville questionnaire, 15 and overall quality of life as assessed with the EuroQoL questionnaire; 
Safety analysis
Safety assessments included all adverse and serious adverse events, subjective symptoms, vital signs, resting 12-lead electrocardiographs, ophthalmic examination, and blood tests. The potential safety concerns for growthfactor therapy were occurrence of cancer, cardiovascular ischaemic events, occurrence of active or proliferative retinopathy or neovascularisation in the retina, and renal failure. Occurrence of any of these was noted in the case report form. A history of cancer or an active tumour was an exclusion criterion (panel 1).
An ophthalmic examination (visual acuity, fundoscopy, and slit-lamp microscopy) was done during the Placebo screening period to exclude active or proliferative retinopathy, or severe macular oedema. The same ophthalmic examinations were repeated at the visits of 1, 3, 6, 9, and 12 months. Myocardial infarction, unstable angina, ischaemic stroke, and acute ischaemia of the lower limbs were adjudicated by the events adjudication committee for confi rmation of diagnosis. Treatment-emergent adverse events, defi ned as all adverse and serious adverse events occurring between randomisation and the patient's date of end of study were analysed. All adverse events were coded with the Medical Dictionary for Regulatory Activities.
Statistical analysis
The calculation of sample size for the combined event rate (amputation and death) was based on the TALISMAN PM201 study 16 in which a hazard ratio (HR) of 0·558 was recorded. With the assumption of a combined event rate (major amputation or death) at 1 year of at least 35% in the placebo group, a fi xed HR of 0·56, a fi xed patient follow-up of 12 months, and a drop-out rate of 5%, a sample size of 490 patients (245 patients in each treatment group) would give a minimum power of 90% to show a 44% reduction in events with NV1FGF compared with placebo, with a twosided log-rank test at a 5% signifi cance level.
All summaries and statistical analyses were generated with SAS version 8.2 on UNIX environment. All effi cacy analyses were done by intention to treat. All safety analyses were based on patients who were treated, according to treat ment actually received (treated population). We compared the primary effi cacy variable (time to fi rst major amputation of the treated leg above the ankle or to death from any cause) between the two treatment groups using a stratifi ed log-rank test. To examine the relation between treatment eff ect and subgroups (age, sex, baseline creatinine, gangrene, and ankle brachial index), we analysed the primary effi cacy variable using a Cox pro portional hazards model in a univariate way with terms for treatment, subgroup, and treatment-by-subgroup inter action. We estimated HRs and 95% CIs for every subgroup.
We analysed the two secondary effi cacy variables (time from randomisation to major amputation or time from randomisation to death) as described above, assessing each of the two parts of the composite primary endpoint separately. We also compared additional secondary effi cacy variables (time from randomisation to any amputation, ulcer healing, pain intensity, functionality and health assess ment, hospital admission because of critical limb ischaemia, index pressure) between the two groups. The incidence of adverse events was analysed with the Fisher's exact test; relative risks and associated 95% CIs were estimated.
This trial is registered with ClinicalTrials.gov, number NCT00566657.
Role of the funding source
A representative of the sponsor was a member of the trial steering committee and was present when decisions were made about trial design. The sponsor was responsible for data monitoring, data collection, and data analysis under the instruction of the trial steering committee. The sponsor of the study had no role in data interpretation or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
880 patients were screened during a period of 2-8 weeks to check the stability of the skin lesions and to screen for cancer and 525 were randomly assigned (fi gure 2). Most of these patients were at least 65 years old (364, 69%), men (365, 70%), white (481, 92%), were former or present smokers (321, 61%), and about 92 (18%) were obese (defi ned as a body-mass index >30 kg/m²). Key baseline patient characteristics were well balanced (table 1) . 18 Other manifestations of atherosclerosis were very frequent, including 234 (45%) patients with a history of coronary artery disease. Renal impairment, as estimated by a creatinine clearance lower than 50 mL/min was present in 152 (29%), including 44 (8%) patients needing haemodialysis. A history of cancer of more than 5 years before study entry (these patients were eligible) was noted in 30 (6%) patients. Of note, those with a history of cancer within the past 5 years were excluded from the study. 258 (49%) of 525 patients had undergone previous revascularisation procedures of the index leg (either angioplasty or surgery) and 115 (22%) had a previous minor amputation. 190 (36%) patients had also undergone a previous revascularisation of the contralateral leg. Additionally, patients who were included had a major impairment in functional status, with only 40% of patients capable of a daily walking activity (n=212) or unassisted physical performance (n=220).
Except for a higher frequency of previous minor amputations in patients included in North America (21 [31% of the North American total]) than in the other regions (115 [22%]), the previous management and the status of the index leg to be treated was similar in all sites across the various regional areas. 18 Similarly, apart from a higher rate of previous bypass surgery in the non-diabetic population, no major diff erence in the previous management and status according to the diabetic status was noted. 18 Unsuitability for revascularisation was retrospectively confi rmed for 497 (95%) patients randomly assigned by the event adjudication committee (webappendix p 1) and was related to anatomical criteria (319 patients, 61%) and an expected low technical success rate of a revascularisation procedure (487, 98%) of all unsuitable patients. General safety concerns associated with the procedure in patients with a favourable anatomy were present in only eight (2%) patients and they did not diff er according to geographical area or diabetes status (data not shown).
Almost all patients met the haemodynamic criterion defi ned at study entry, whereas only a few were enrolled on the basis of a TcPO 2 lower than 30 mm Hg as a single haemodynamic test to meet the inclusion criterion (table 1) . 517 (98%) patients had infrainguinal arteries aff ected by stenotic lesions of more than 70%. Thigh arteries were aff ected in 354 patients (67%), and arteries below the knee were aff ected in almost all patients (493, 94%). Furthermore, multilevel locations of arterial lesions were common, and 495 (94%) patients had more than one diseased artery. Haemodynamic variables and diseased arterial territories did not diff er according to regional area or diabetes status. 18 Cardiovascular drugs were used in more than 80% of cases, including β blockers, which were given to 242 patients (46%) and angiotensin conversion enzyme inhibitors, given to 270 (51%; webappendix p 2 to 201 (38%) patients. 14 (5%) of 259 patients given placebo received intravenous prostaglandin treatment, as did 29 (11%) of 266 patients in the active group (webappendix p 3). The duration of study treatment was 41 days (range 1-49) days in the placebo group and 40 days (1-52) in the active group. 228 (88%) of 259 patients in the placebo group and 228 (86%) of 266 in the NV1FGF group received four administrations of treatment.
The two groups did not diff er signifi cantly in the primary effi cacy endpoint of time to major amputation on the treated leg or death, whichever came fi rst (table 2 and fi gure 3). This endpoint did not vary signifi cantly with the demographic variables (table 3) . The time to fi rst major amputation on the treated leg or death was similar between treatment and placebo groups (table 2 and fi gure 4). Post-hoc primary effi cacy analysis on the subgroup of 444 patients (86%) who received the full course of treatment (four administrations of 4 mg) shows similar results (data not shown). Table 4 shows causes of death in the two groups.
The main secondary effi cacy endpoints (time to fi rst major amputation of the treated leg and time to death) were assessed separately and by the event adjudication committee. Because the primary effi cacy endpoint was not signifi cant, no signifi cance could be claimed for the main secondary effi cacy endpoints. However, time from randomisation to fi rst major amputation on the treated leg was similar between the NV1FGF group and placebo, and the time from randomisation to any cause of death was similar between the NV1FGF group and placebo (table 2). In view of the large proportion of patients with diabetes, randomisation was stratifi ed by diabetes status. In patients with diabetes, the HR for the primary endpoint was 1·18 (95% CI 0·79-1·77), whereas in patients without diabetes, the HR was 1·01 (0·66-1·56; p=0·6796 for interaction; data not shown).
To inform future trials we continued the analysis for an exploratory additional 6-month review period to see whether any diff erence in the primary event measures could be detected at this later time, if the primary endpoint was not achieved. This analysis gave no positive result.
Importantly, no patient was lost to follow-up in this trial. The number of patients having treatmentemergent adverse events that occurred after randomisation was similar in both groups: 214 (80%) in the NV1FGF group versus 205 (79%) in the placebo group. The number of patients with any treatment-emergent adverse event leading to permanent treatment discontinuation was higher in the NV1FGF group (24 of 257 patients who received treatement [9%]) than in the placebo group (15 of 266 [6%] ). The reasons for discontinuation were infection in seven (44%) of 16 patients given placebo and 12 (50%) of 24 active patients who discontinued, and increasing ischaemia (fi ve [33%] of 15 patients given placebo, fi ve [21%] of 24 patients given NV1FGF). The safety analysis did not show any signifi cant increase in any treatment-emergent adverse event, particularly for factors previously identifi ed as potential risks associated with gene therapy and angiogenic growth factors, such as proliferative retinopathy or severe macular oedema, acute ischaemic events, and renal impairment (table 2). 
Discussion
The primary endpoint (fewer deaths or fi rst major amputation of the treated leg whichever came fi rst) was not achieved, nor were the secondary endpoints. This result contrasts with the phase 2 TALISMAN study in which signifi cant benefi t was recorded in the secondary endpoint (major amputation) and in the combined endpoint (major amputation or death, whichever came fi rst).
Examination of the populations studied in the two trials showed no clear evidence of any baseline diff erences that could have caused the discrepancy in the results. Similar inclusion and exclusion criteria were required for both studies (in addition to the similar design, treatment dosing, and regimen used in TAMARIS to replicate phase 2 results). The phase 3 trial had about 10% more patients with diabetes than did the phase 2 trial, but a subgroup analysis of non-diabic patients alone did not change the results. Furthermore, TAMARIS included patients with end-stage renal disease (by contrast with TALISMAN). However, assessment of data with removal of these subgroups did not change the results. Nor did geographical distribution of study sites contribute to the diff erences recorded. When the analysis was restricted to the TALISMAN sites only, the results were still negative.
A key observation, however, was that the major amputation or death rate in the placebo group at 360 days in TALISMAN (more than 50%) diff ered from that in the placebo group in TAMARIS (33%). By contrast, the treated-group endpoint rates were similar in both studies, suggesting that the signifi cance achieved in TALISMAN depended on a high placebo endpoint rate. It is unlikely that medical or background treatment improved in the 4 years between studies, since assessment of the baseline characteristics suggests similar use of statins and other vascular risk modifi ers in the two studies. Geographical variation in event rates between studies could exist, although the low number of patients included in some regions might not support the conclusion that the observed placebo rates indicate the disease management in these countries. In the TAMARIS placebo group, the primary endpoint ranged from 20% in Latin America to 48% in North America. The TALISMAN study was done in Europe and had only 56 patients randomly assigned to placebo. Moreover, infection-related amputations were more common in the placebo group of TALISMAN 16 than in the placebo group of TAMARIS. Thus, the ability to estimate a true untreated event rate in this population is very challenging.
Analyses of the data did not show any selection bias within the two groups since they were well matched for baseline characteristics. Because the event rate (major amputation or death) was lower than expected in the placebo group, it could be argued that the wrong patient population was selected, and that more severe disease should have been studied. However, no trend to effi cacy was detected in the most ischaemic patients (table 3 shows results for presence of gangrene).
No clear adverse safety signals were noted with NV1FGF. Safety analyses showed no diff erence in cardiovascular events or death between active and placebo groups. The previously identifi ed potential risks associated with gene therapy and angiogenic growth factors include proliferative retinopathy, malignancy, macular oedema, acute ischemic events, and renal impairment. Thus, a long-term safety follow-up of 36 months has been implemented and is still in progress.
This follow-up is in line with the European Medicinal Agency (EMEA) guidance for long-term safety assessment of patients treated with gene therapy products.
In conclusion, results from this large gene-therapy study in critical limb ischaemia to be completed to date (panel 2), portray the challenges faced by the development programmes of single genes, such as extrapolation from conclusive animal studies to defi ne the optimum dose, vector, route, and duration of administration, as well as whether the administration of any one gene could result in therapeutic angiogenesis leading to the prevention of limb amputations.
